Modality
mAb
MOA
MDM2i
Target
IL-17A
Pathway
JAK/STAT
NB
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
~Jun 2017
→ ~Sep 2018
Phase 2
~Dec 2018
→ ~Mar 2020
Phase 3
~Jun 2020
→ ~Sep 2021
NDA/BLA
~Dec 2021
→ ~Mar 2023
Approved
Jun 2023
→ Jun 2030
ApprovedCurrent
NCT03351582
84 pts·NB
2023-06→2026-04·Terminated
NCT07657925
320 pts·NB
2025-03→2030-06·Recruiting
404 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2026-04-122w awayPh3 Readout· NB
2030-06-084.2y awayPh3 Readout· NB
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
Approved
Termina…
Approved
Recruit…
Catalysts
Ph3 Readout
2026-04-12 · 2w away
NB
Ph3 Readout
2030-06-08 · 4.2y away
NB
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03351582 | Approved | NB | Terminated | 84 | HAM-D |
| NCT07657925 | Approved | NB | Recruiting | 320 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| Rimasertib | Exelixis | Phase 3 | B7-H3 | |
| 180-6098 | Innovent Bio | Phase 1 | ALK |